Apple Inc. (NASDAQ:AAPL) [Trend Analysis] climbed reacts as active mover, shares an advance 1.52% to traded at $111.73 and the percentage gap among open changing to regular change was 0.05%. A new lock screen bypass has been discovered that allows iPhone users to view contact and photo albums on the iPhone SE, iPhone 6 Plus and iPhone 6s Plus without unlocking the devices with a passcode or Touch ID fingerprint. Miguel of iDeviceHelp in a YouTube video showed the exploit taking advantage of unauthenticated access to Siri via the lock screen, and Siri’s access to contacts and photos.
Notably, this is not the first lock screen bypass exploit discovered by users as earlier this year a same exploit saw users gaining access of the device without Touch ID or passcode. There are several examples of lock screen bypass reported by users on iPhones every year that offer access to Photos, contacts, or entire device without actually unlocking the smartphone.
The new exploit however does require a very particular set of circumstances. For one, Siri should be enabled on the lock screen which assists you gain access to Photos and Contacts without unlocking the device. The attacker should have an extra iPhone to help in gaining access to Photos and Contacts on the locked iPhone. The firm’s current ratio calculated as 1.40 for the most recent quarter. The firm past twelve months price to sales ratio was 2.76 and price to cash ratio remained 8.86. As far as the returns are concern, the return on equity was recorded as 35.60% and return on investment was 20.60% while its return on asset stayed at 14.90%. The firm has total debt to equity ratio measured as 0.68.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.62% to close at $38.80 with the total traded volume of 6.11 Million shares. Teva Pharmaceutical Industries Ltd., (TEVA) reported that firm has obtained authorization from the European Commission for an indication extension of Trisenox (arsenic trioxide). The indication extension is for newly diagnosed low to intermediate risk Acute Promyelocytic Leukemia in combination with retinoic acid.
Teva Pharma noted that this marks an important advancement in treatment for Acute Promyelocytic Leukemia patients in Europe, as it is the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. The decision by the European Commission grants marketing authorization for first line use of Trisenox in the 28 countries of the Eu. The firm has institutional ownership of 57.20%, while insider ownership included 2.70%. Its price to sales ratio ended at 2.00. TEVA attains analyst recommendation of 2.00 with week performance of -5.44%.